Inhibition of Cholesterol Transport from Lysosomes by Itraconazole Repolarizes Tumor-associated Macrophages to Anti-tumor M1 type
Open Access
- 29 November 2025
- journal article
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 45 (12) , 5255-5266
Abstract
Background/Aim: Targeting tumor-associated macrophages (TAMs) represents a promising strategy for next-generation immunotherapy. This study investigates the underlying mechanisms of TAM repolarization from the pro-tumorigenic M2 phenotype to the anti-tumorigenic M1 phenotype induced by itraconazole (ITZ). Materials and Methods: M2 macrophages derived from THP-1 cells were used in all experiments, and ITZ was administered at a concentration of 10−5 M. Morphological changes were monitored via time-lapse imaging. Single-cell RNA sequencing (scRNA-seq) and triple-color immunostaining for organelles, cholesterol, and the M1 marker interleukin (IL)-1β were performed with and without ITZ treatment. For inhibition studies, β-cyclodextrin polyrotaxane (βCD-PRX), a compound that removes cholesterol from lysosomes, was used. The effects were assessed by time-lapse imaging and western blot analysis of the M2 marker CD163. Results: Following ITZ treatment, a subpopulation of M2 macrophages exhibited morphological changes, shedding dendrites and migrating, indicative of an M1-like phenotype. Additionally, intracellular lipid droplets enlarged and swelled. scRNA-seq analysis revealed that M2 macrophages with reduced lysosomal vesicle biogenesis transitioned to an M1-like phenotype and identified 1,142 significantly enriched pathways, including M1-related signaling activation and cholesterol metabolism and transport pathways. Immunofluorescence analysis confirmed that macrophages shifting toward an M1-like phenotype expressed IL-1β, with enlarged intracellular lipid droplets identified as cholesterol-containing lysosomes. Notably, M2 macrophages that had adopted an M1-like morphology in response to ITZ reverted to their original M2-like shape and exhibited increased CD163 expression following βCD-PRX treatment. Conclusion: Inhibition of lysosomal cholesterol release by ITZ reprogrammed M2 macrophages into an M1-like phenotype, revealing a novel mechanism that may serve as a foundation for developing innovative TAM-targeted immunotherapies.Keywords
This publication has 23 references indexed in Scilit:
- Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphomaNature Communications, 2024
- Best practices for single-cell analysis across modalitiesNature Reviews Genetics, 2023
- RETRACTED: Repurposed itraconazole for use in the treatment of malignancies as a promising therapeutic strategyBiomedicine & Pharmacotherapy, 2022
- Itraconazole Induces Regression of Infantile Hemangioma via Downregulation of the Platelet-Derived Growth Factor–D/PI3K/Akt/mTOR PathwayJournal of Investigative Dermatology, 2019
- Membrane Cholesterol Efflux Drives Tumor-Associated Macrophage Reprogramming and Tumor ProgressionCell Metabolism, 2019
- Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotypeNature Communications, 2018
- Polyrotaxane-based systemic delivery of β-cyclodextrins for potentiating therapeutic efficacy in a mouse model of Niemann-Pick type C diseaseJournal of Controlled Release, 2018
- SCENIC: single-cell regulatory network inference and clusteringNature Methods, 2017
- The cholesterol transporter ABCG1 links cholesterol homeostasis and tumour immunityNature Communications, 2015
- Cholesterol trafficking is required for mTOR activation in endothelial cellsProceedings of the National Academy of Sciences, 2010